Egypt has taken a major step toward strengthening its vaccine manufacturing capabilities with

the foundation stone ceremony of GENNVAX, set to become the largest fully integrated vaccine

production facility in the region With a total investment exceeding USD 150 million, the project

aims to advance biopharmaceutical localization, enhance drug security, and position Egypt as a

regional hub for vaccine production

High-Level Ceremony Highlights Strategic Investment

The ceremony, held at the First Industrial Sector of Orascom Industrial Parks, was attended

by a high-level delegation including ministers, ambassadors, and leaders from Egypt’s healthcare

and pharmaceutical sectors Notable attendees included

Eng Hassan El Khatib, Minister of Investment and Foreign Trade

Dr. Khaled Abdel Ghaffar, Deputy Prime Minister for Human Development and

Minister of Health and Population

Mr Walid Gamal El-Din, Chairman of the Suez Canal Economic Zone

Eng Amr El-Batrik, CEO of Orascom Industrial Parks

Senior officials from the Egyptian Drug Authority, Unified Procurement Authority, WHO

and the Armed Forces Medical Services Administration were also present, alongside

GENNVAX international partners and technology transfer licensors

GENNVAX: Advancing Vaccine Localization and Production

Designed as a fully integrated vaccine manufacturing complex, GENNVAX will cover the entire

production cycle, from upstream to downstream processes, producing 29 vaccines and serums

through agreements with 15 international partners The facility will support Egypt’s national

immunization programs, while expanding export potential to Africa and the Middle East

With an annual capacity of 270 million doses per production line operating on a two-shift system

the facility integrates advanced digital infrastructure to ensure quality, efficiency, and traceability

aligning with WHO Prequalification (WHO PQ) standards to facilitate international distribution

Strengthening Egypt’s Pharmaceutical Industry and Drug Security

Officials highlighted the project’s strategic role in achieving Egypt Vision 2030, enhancing

drug security, reducing reliance on imports, and attracting foreign direct investment in the

biopharmaceutical sector GENNVAX is expected to create 500–700 direct jobs, contributing

to local employment and the development of skilled national talent capable of competing internationally

Sustainability at the Core

The GENNVAX facility has been designed as a green facility, utilizing solar energy

and environmentally responsible technologies, reflecting Egypt’s green transformation

strategy and commitment to sustainable industrial practices

Leadership Perspective and Long-Term Vision

Mr. Adam El Daba, Chairman of El Daba Holding and GENNVAX, noted that Egypt’s

macroeconomic improvements and investment-friendly climate were key drivers for

moving forward with this strategic project Dr Nibal Dahaba, shareholder and Managing

Director of GENNVAX, described the foundation stone ceremony as the start of a new

chapter for biopharmaceutical manufacturing in Egypt, emphasizing the company’s reliance

on advanced technology, international partnerships, and a long-term vision to deliver innovative

vaccine solutions for Egypt and Africa

Knowledge Localization and Capacity Building

GENNVAX has also launched the GENNVAX Academy for Continuing Medical Education

providing advanced training programs for professionals from leading national and international

regulatory bodies, including the Egyptian Drug Authority (EDA) and the Unified Procurement

Authority (UPA) This initiative ensures the sustained application of global quality standards

across local pharmaceutical production

Corporate Background

GENNVAX is part of El Daba Holding, a leading national group established in 1957, with

operations across Egypt, Canada, Russia, Saudi Arabia, the UAE, and several African countries

The project reinforces the state’s strategy to localize pharmaceutical manufacturing, expand

capacity in critical biotechnological industries, and enhance Egypt’s role as a regional hub for

vaccine development and production